DD253626A5 - Verfahren zur herstellung von 7 delta-substituierten-3-oxo-17delta-pregn-4-en-21.17-carbolactonen - Google Patents

Verfahren zur herstellung von 7 delta-substituierten-3-oxo-17delta-pregn-4-en-21.17-carbolactonen Download PDF

Info

Publication number: DD253626A5
Authority: DD; German Democratic Republic
Prior art keywords: oxo; carbolactone; pregn; ene; methylene
Prior art date: 1983-08-17

Application number

DD84266308A

Other languages

German (de)

English (en)

Inventor

Klaus Nickisch

Henry Laurent

Peter Esperling

Dieter Bittler

Rudolf Wiechert

Wolfgang Losert

Original Assignee

��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-17

Filing date

1984-08-15

Publication date

1988-01-27

1983-08-17 Priority claimed from DE3330084A external-priority patent/DE3330084A1/de

1983-08-17 Priority claimed from DE19833330086 external-priority patent/DE3330086A1/de

1983-08-17 Priority claimed from DE19833330085 external-priority patent/DE3330085A1/de

1984-08-15 Application filed by ��@��k�� filed Critical ��@��k��

1988-01-27 Publication of DD253626A5 publication Critical patent/DD253626A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 17
150000001875 compounds Chemical class 0.000 claims abstract description 18
238000002360 preparation method Methods 0.000 claims abstract description 6
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
-1 2-hydroxyethylthio Chemical group 0.000 claims description 28
HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 11
230000001864 anti-aldosterone effect Effects 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
238000002844 melting Methods 0.000 description 20
230000008018 melting Effects 0.000 description 20
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 9
229960002256 spironolactone Drugs 0.000 description 9
239000000126 substance Substances 0.000 description 7
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
AVGAIPMGSIOHFZ-UHFFFAOYSA-N dichloromethane;2-propan-2-yloxypropane Chemical compound ClCCl.CC(C)OC(C)C AVGAIPMGSIOHFZ-UHFFFAOYSA-N 0.000 description 6
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000002280 anti-androgenic effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 3
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
229960002478 aldosterone Drugs 0.000 description 3
238000006356 dehydrogenation reaction Methods 0.000 description 3
239000005457 ice water Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000002170 aldosterone antagonist Substances 0.000 description 2
239000003098 androgen Substances 0.000 description 2
WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
FETFXNFGOYOOSP-UHFFFAOYSA-N 1-sulfanylpropan-2-ol Chemical compound CC(O)CS FETFXNFGOYOOSP-UHFFFAOYSA-N 0.000 description 1
241000430521 Alyssum Species 0.000 description 1
BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
241000186063 Arthrobacter Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000193422 Bacillus lentus Species 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
208000016998 Conn syndrome Diseases 0.000 description 1
241001402444 Diplomitoporus flavescens Species 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000589565 Flavobacterium Species 0.000 description 1
241001077885 Gesta Species 0.000 description 1
206010020571 Hyperaldosteronism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000193386 Lysinibacillus sphaericus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
235000017276 Salvia Nutrition 0.000 description 1
240000007164 Salvia officinalis Species 0.000 description 1
206010039808 Secondary aldosteronism Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
PNZVFASWDSMJER-UHFFFAOYSA-N acetic acid;lead Chemical compound [Pb].CC(O)=O PNZVFASWDSMJER-UHFFFAOYSA-N 0.000 description 1
LVAMVZXECCXUGI-UHFFFAOYSA-N acetic acid;thallium Chemical compound [Tl].CC(O)=O LVAMVZXECCXUGI-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
102000001307 androgen receptors Human genes 0.000 description 1
108010080146 androgen receptors Proteins 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
HBFXVTVOSLPOEY-UHFFFAOYSA-N ethoxyethane;2-propan-2-yloxypropane Chemical compound CCOCC.CC(C)OC(C)C HBFXVTVOSLPOEY-UHFFFAOYSA-N 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000003152 gestagenic effect Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
208000013846 primary aldosteronism Diseases 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
238000001665 trituration Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/005—3 membered carbocyclic rings in position 12
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrane Compounds (AREA)

DD84266308A 1983-08-17 1984-08-15 Verfahren zur herstellung von 7 delta-substituierten-3-oxo-17delta-pregn-4-en-21.17-carbolactonen DD253626A5 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE3330084A DE3330084A1 (de)	1983-08-17	1983-08-17	7(alpha)-alkoxycarbonyl-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone und deren 21-carbonsaeuresalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE19833330086 DE3330086A1 (de)	1983-08-17	1983-08-17	7(alpha)-mercapto- und 7(alpha)-alkylthio-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19833330085 DE3330085A1 (de)	1983-08-17	1983-08-17	7(alpha)-(1-oxoalkyl)-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone und deren 21-carbonsaeuresalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate

Publications (1)

Publication Number	Publication Date
DD253626A5 true DD253626A5 (de)	1988-01-27

Family

ID=27191224

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DD84266308A DD253626A5 (de)	1983-08-17	1984-08-15	Verfahren zur herstellung von 7 delta-substituierten-3-oxo-17delta-pregn-4-en-21.17-carbolactonen
DD84285918A DD242410C4 (de)	1983-08-17	1984-08-15	Verfahren zur herstellung von 7 alpha-substituirten 3-oxo-17 alpha-pregn-4-en -21.17-carbolactonen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DD84285918A DD242410C4 (de)	1983-08-17	1984-08-15	Verfahren zur herstellung von 7 alpha-substituirten 3-oxo-17 alpha-pregn-4-en -21.17-carbolactonen

Country Status (14)

Country	Link
US (1)	US4559331A (da)
EP (2)	EP0134529B1 (da)
AT (1)	ATE51233T1 (da)
AU (1)	AU578034B2 (da)
DD (2)	DD253626A5 (da)
DE (1)	DE3481707D1 (da)
DK (1)	DK395584A (da)
ES (1)	ES8504212A1 (da)
FI (1)	FI843208A7 (da)
GR (1)	GR80115B (da)
HU (1)	HU193694B (da)
IL (1)	IL72709A (da)
NO (1)	NO843277L (da)
PT (1)	PT79091B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3414508A1 (de) *	1984-04-13	1985-10-24	Schering AG, 1000 Berlin und 4709 Bergkamen	Mehrfach tritiierte steroid-20.17-spirolactone und ihre verwendung als tracersubstanzen
US4670551A (en) *	1984-06-21	1987-06-02	Ciba-Geigy Corporation	Epoxy steroids
US5506222A (en) *	1991-09-25	1996-04-09	Laboratorios Beta S.A.	Method and composition for treating increased androgenic activity
ITMI20040367A1 (it) *	2004-03-01	2004-06-01	Ind Chimica Srl	Processo per la preparazione di drospirenone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3013012A (en) *	1960-12-22	1961-12-12	Searle & Co	Alkanoylthio-17alpha-carboxyethyl-17beta-hydroxyandrosten-3-one lactones
US3509136A (en) *	1968-07-30	1970-04-28	Searle & Co	3 - (17beta - hydroxy - 7alpha - (lower alkyl) thio-3-oxoandrost-4-en-17alpha-yl)propionic acid gamma-lactones and congeners
GB1368006A (en) *	1972-08-24	1974-09-25	Searle & Co	4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
DE2652761C2 (de) *	1976-11-16	1985-11-21	Schering AG, 1000 Berlin und 4709 Bergkamen	15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) *	1979-05-31	1980-12-04	Schering Ag	6 beta .7 beta
DE3168754D1 (en) *	1980-07-09	1985-03-21	Beecham Group Plc	Clonidine derivatives useful in the treatment of diarrhoea
DE3111951A1 (de) *	1981-03-23	1982-09-30	Schering Ag, 1000 Berlin Und 4619 Bergkamen	7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPS5921698A (ja) *	1982-07-22	1984-02-03	シエ−リング・アクチエンゲゼルシヤフト	１７α−プレグネ−４−エン−３−オキソ−２１−カルボン酸エステル、その製法およびこれを含有する抗アンドロゲン作用を有する医薬
DE3227598A1 (de) *	1982-07-22	1984-01-26	Schering AG, 1000 Berlin und 4709 Bergkamen	7(alpha)-acylthio-15.16-methylen-3-oxo-17(alpha)-pregna-1.4-dien-21,17-carbolactone, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPS59139400A (ja) *	1983-01-31	1984-08-10	Shionogi & Co Ltd	抗アルドステロン活性ステロイド誘導体

1984
- 1984-07-26 EP EP84108845A patent/EP0134529B1/de not_active Expired - Lifetime
- 1984-07-26 AT AT84108845T patent/ATE51233T1/de not_active IP Right Cessation
- 1984-07-26 DE DE8484108845T patent/DE3481707D1/de not_active Expired - Lifetime
- 1984-08-14 GR GR80115A patent/GR80115B/el unknown
- 1984-08-14 FI FI843208A patent/FI843208A7/fi not_active Application Discontinuation
- 1984-08-15 DD DD84266308A patent/DD253626A5/de unknown
- 1984-08-15 DD DD84285918A patent/DD242410C4/de unknown
- 1984-08-16 AU AU32001/84A patent/AU578034B2/en not_active Ceased
- 1984-08-16 NO NO843277A patent/NO843277L/no unknown
- 1984-08-16 HU HU843108A patent/HU193694B/hu unknown
- 1984-08-16 ES ES535187A patent/ES8504212A1/es not_active Expired
- 1984-08-16 PT PT79091A patent/PT79091B/pt unknown
- 1984-08-17 IL IL72709A patent/IL72709A/xx unknown
- 1984-08-17 US US06/641,599 patent/US4559331A/en not_active Expired - Fee Related
- 1984-08-17 DK DK395584A patent/DK395584A/da not_active Application Discontinuation
1988
- 1988-10-17 EP EP88730228A patent/EP0308365A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
DK395584A (da)	1985-02-18
EP0134529A2 (de)	1985-03-20
US4559331A (en)	1985-12-17
AU3200184A (en)	1985-02-21
EP0134529A3 (en)	1985-08-21
HUT34995A (en)	1985-05-28
AU578034B2 (en)	1988-10-13
ATE51233T1 (de)	1990-04-15
EP0134529B1 (de)	1990-03-21
PT79091A (de)	1984-09-01
PT79091B (de)	1986-08-14
DE3481707D1 (de)	1990-04-26
GR80115B (en)	1984-12-14
NO843277L (no)	1985-02-18
FI843208A0 (fi)	1984-08-14
HU193694B (en)	1987-11-30
FI843208A7 (fi)	1985-02-18
DD242410A5 (de)	1987-01-28
EP0308365A1 (de)	1989-03-22
ES535187A0 (es)	1985-05-01
ES8504212A1 (es)	1985-05-01
DK395584D0 (da)	1984-08-17
IL72709A (en)	1988-08-31
IL72709A0 (en)	1984-11-30
DD242410C4 (de)	1987-11-11

Publication	Publication Date	Title
EP0147361B1 (de)	1989-02-08	11 Beta-Aryl-Estradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate
EP0970104B1 (de)	2006-11-22	Steroidsulfamate, verfahren zu ihrer herstellung und anwendung derselben
EP0122232A1 (de)	1984-10-17	20-Spiroxane und Analoge mit geöffnetem Ring E, Verfahren zu ihrer Herstellung, sowie pharmazeutische Präparate davon
DD151172A5 (de)	1981-10-08	Verfahren zur herstellung von 6beta.7beta;15.16-dimethylen-1.4-androstadien-3-onen
WO1986004900A1 (fr)	1986-08-28	SPIROLACTONE 1alpha.7alpha-DITHIO SUBSTITUEES, PROCEDE POUR LEUR PREPARATION ET LEUR UTILISATION COMME MEDICAMENT
EP0134529B1 (de)	1990-03-21	7-alpha-Substituierte 3-Oxo-17alpha-pregn-4-en-21.17-carbolactone, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
EP0051762B1 (de)	1984-12-19	11-Methylen-delta-15-Steroide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE69215125T2 (de)	1997-06-12	Kardioaktive Steroide
DD210061B3 (de)	1988-11-30	Verfahren zur herstellung con 7 alpha-acylthio-15,16-methylen-3-oxo-17 alpha-pregna-1.4-dien-21.17-carbolactone
DE1152101B (de)	1963-08-01	Verfahren zur Herstellung von mit einem Pyrazolring kondensierten Steroidverbindungen
DE3402330A1 (de)	1985-07-25	1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
EP0061418B1 (de)	1985-08-21	7-Alpha-Alkoxycarbonyl-15-beta.16-beta-methylen-4-androstene, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
EP0108033B1 (de)	1987-12-02	Neue 7-alpha-Acylthio-1-alpha,2-alpha-Methylen-3-oxo-17-alpha-pregn-4-en-21,17-carbolactone, deren Herstellung und diese enthaltende Arzneimittel
EP0255464B1 (de)	1990-08-16	2,2;6,6-Diethylen-3-oxo-17alpha-pregn-4-en-21, 17-carbolactone, Verfahren zu deren Herstellung und diese enthaltende pharm. Präparate
DE2309328A1 (de)	1973-10-04	3-keto-7(alpha,beta)-nied.-alkyldelta hoch 5-steroide und verfahren zu ihrer herstellung
CH639399A5 (de)	1983-11-15	Steroid-spiro-oxazolidinon-derivate.
EP0092174B1 (de)	1986-03-05	11Beta-Chlor-Delta15-Steroide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE3330086A1 (de)	1985-03-07	7(alpha)-mercapto- und 7(alpha)-alkylthio-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
EP0131899B1 (de)	1987-11-25	15,16-Methylen-17-alpha-pregna-4,6-dien-21-carbonsäuresalze, diese enthaltende pharmazeutische Präparate sowie Verfahren zu deren Herstellung
EP0034114B1 (de)	1983-02-09	3-Desoxy-delta-15-Steroide, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate
DE1923378C3 (de)	1978-06-29	1 alpha, 2alpha, 6beta, 7beta-Dimethylensteroide Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE3427090A1 (de)	1986-01-23	7(alpha)-thiosubstituierte 19-hydroxy-15(beta),16(beta)-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AT270887B (de)	1969-05-12	Verfahren zur Herstellung von neuen 9β,10α-Steroiden
EP2238147A2 (de)	2010-10-13	17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-derivat, dessen verwendung und das derivat enthaltende arzneimittel
DE19548449A1 (de)	1997-06-26	17alpha-Cyanomethyl-3-oxyiminoestra-4,9-dien-3-on-17beta-yl-derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen